With the New Year, the wheels of justice began to turn.
The Securities and Exchange Commission, the FBI, and the U.S. Attorney's Office for the Southern District of New York were investigating all of those bizarre coincidences that surrounded the trading of ImClone shares just prior to the FDA's rejection of Erbitux.
In the early part of the investigation, Martha Stewart had little to worry about. The Government had nothing more than a handful of coincidences and no real evidence of insider trading—only suspicions.
At first, however, the coincidences did seem odd.
Those who were investigating had more questions than answers.
In a relatively short time, the investigators put part of the puzzle together, but not all ...